Company: LCTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0000950170-25-060090
Chunk: 74

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 74
---
'>-53-</div>

Any notice of director nomination submitted to us must also include the additional information required by Rule 14a-19(b) under the Exchange Act. Therefore, in addition to satisfying the deadlines for timely notice of a proposed director nominee, shareholders who intend to solicit proxies in support of nominees submitted in accordance with the foregoing advance notice provisions must further provide notice of proxy solicitation in support of director candidates other than Lineage’s nominees, as required under Rule 14a-19, no later than March 28, 2026, which is 90 days prior to the one-year anniversary of the Meeting.

<div align='center'>ANNUAL REPORT</div>

Our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, without exhibits, may be obtained by a shareholder without charge, upon written request to the Corporate Secretary of Lineage. At a shareholder’s request, we will also furnish any exhibit to such Annual Report upon the payment of a fee to cover our reasonable expenses in furnishing such exhibit.

<div align='center'>-54-

APPENDIX A</div>

(The following is the text of the proposed Plan Amendment. This text is followed by the current text of the 2021 Plan (without giving effect to the proposed Plan Amendment.)

<div align='center'>Amendment No. 2 to
Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan</div>

Section 3(a)(i) of the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan is deleted in its entirety and replaced with the following:

Subject to Section 3(a)(iii) and Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards from and after the Effective Date (the “Share Reserve”) will not exceed the sum of (A) 54,000,000 shares and (B) the Prior Plan Returning Shares, if any, as such shares become available for issuance under this Plan from time to time.

<div align='center'>*****

Lineage Cell Therapeutics, Inc.

2021 Equity Incentive Plan, As Amended(1)

Originally adopted by the Board of Directors: July 21, 2021

Originally approved by the Shareholders: September 13, 2021</div>

1.General.

(a) Prior Plan.As of the Effective Date: (i) no additional awards may be granted under the